Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic-metabolic axis with natural compounds and emerging therapies.
4 affiliations
- 1Changchun University of Chinese Medicine, Changchun, China.
- 2Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
- 3School of Basic Medicine, Faculty of Medicine, Dalian University of Technology, Dalian, China.
- 4China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China.
Abstract
Cancer cell plasticity enables tumor cells to dynamically transition between diverse phenotypic states, including epithelial-mesenchymal plasticity stemness, dormancy, lineage switching, immune evasion, and therapy-resistant phenotypes. Although metabolic reprogramming and epigenetic regulation have each been recognized as hallmarks of cancer, the mechanistic framework linking metabolic adaptation to dynamic cell-state transitions remains incompletely understood. In this Review, we propose that methylation serves as a major mechanistic interface through which metabolic rewiring can influence adaptive cancer cell plasticity. We discuss how one-carbon metabolism regulates the availability of the universal methyl donor S-adenosylmethionine (SAM), thereby influencing DNA methylation, histone methylation, and multiple forms of RNA methylation, with N6-methyladenosine (m6A) representing the principal RNA modification discussed in this review. Rather than responding uniformly to metabolic change, these methylation systems represent distinct but metabolically connected regulatory layers that share dependence on one-carbon metabolism while differing in their biochemical sensitivities and regulatory outputs. Net methylation states, however, are also shaped by metabolically constrained demethylation, including α-ketoglutarate-, oxygen-, Fe2+-, and flavin adenine dinucleotide (FAD)-dependent eraser pathways. Together, these metabolically responsive writing and erasing processes influence transcriptional stability, chromatin accessibility, and post-transcriptional regulation during reversible cell-state transitions. We further examine how environmental and therapeutic stresses, including hypoxia, nutrient limitation, immune surveillance, and anticancer therapy, reshape methylation programs through metabolic adaptation, and how such remodeling may support phenotypic flexibility and survival under selective pressure. Building upon these advances, we propose the concept of the adaptive methylation landscape, a perturbation-responsive, state-associated, and potentially reversible distribution of methylation states that contributes to shaping the spectrum of cellular states accessible during tumor evolution. Finally, we discuss emerging therapeutic strategies targeting the metabolic-methylation axis and highlight how single-cell multi-omics, spatial epigenomics, functional epigenome editing, and AI may enable dynamic mapping of adaptive methylation landscapes. We propose that cancer cell plasticity is not merely a genetic phenomenon but can also be shaped by metabolically responsive methylation programs, providing a testable conceptual framework for future precision epigenetic therapies.
Related
- Metformin Attenuates Glucose-Driven Hepatocellular Carcinoma Progression by Targeting GPD2-Mediated Metabolic Plasticity.
- Epigenetic plasticity in cancer drug resistance: mechanistic insights and strategies for therapeutic intervention
- Evolutionary Epigenetic Analysis of Oxidative Balance Score-Associated DNA Methylation Sites Across Mammals
- Altered sperm DNA methylation provides an epigenetic route from overweight and older men to intergenerational disease transmission.
- Epigenome-Wide DNA Methylation Profiling of Matched Primary Breast Cancers and Brain Metastases Reveals Epigenetic Markers linked to Metastatic Progression: A Preliminary Study.
BibTeX
@article{liu2026metabolic,
title = {{Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic-metabolic axis with natural compounds and emerging therapies.}},
author = {Qi Liu and Ying Yu and Wenbo Li and Xinxu Chen and Zekai Shi and Gang Li and Shibo Wei and Zongjian Luo},
journal = {Frontiers in cell and developmental biology},
year = {2026},
month = oct,
doi = {10.3389/fcell.2026.1943655},
url = {https://europepmc.org/article/MED/42953404},
note = {CC BY},
}
RIS
TY - JOUR
TI - Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic-metabolic axis with natural compounds and emerging therapies.
AU - Qi Liu
AU - Ying Yu
AU - Wenbo Li
AU - Xinxu Chen
AU - Zekai Shi
AU - Gang Li
AU - Shibo Wei
AU - Zongjian Luo
PY - 2026
DA - 2026/10/14
JO - Frontiers in cell and developmental biology
DO - 10.3389/fcell.2026.1943655
UR - https://europepmc.org/article/MED/42953404
AB - Cancer cell plasticity enables tumor cells to dynamically transition between diverse phenotypic states, including epithelial-mesenchymal plasticity stemness, dormancy, lineage switching, immune evasion, and therapy-resistant phenotypes. Although metabolic reprogramming and epigenetic regulation have each been recognized as hallmarks of cancer, the mechanistic framework linking metabolic adaptation to dynamic cell-state transitions remains incompletely understood. In this Review, we propose that methylation serves as a major mechanistic interface through which metabolic rewiring can influence adaptive cancer cell plasticity. We discuss how one-carbon metabolism regulates the availability of the universal methyl donor S-adenosylmethionine (SAM), thereby influencing DNA methylation, histone methylation, and multiple forms of RNA methylation, with N6-methyladenosine (m6A) representing the principal RNA modification discussed in this review. Rather than responding uniformly to metabolic change, these methylation systems represent distinct but metabolically connected regulatory layers that share dependence on one-carbon metabolism while differing in their biochemical sensitivities and regulatory outputs. Net methylation states, however, are also shaped by metabolically constrained demethylation, including α-ketoglutarate-, oxygen-, Fe2+-, and flavin adenine dinucleotide (FAD)-dependent eraser pathways. Together, these metabolically responsive writing and erasing processes influence transcriptional stability, chromatin accessibility, and post-transcriptional regulation during reversible cell-state transitions. We further examine how environmental and therapeutic stresses, including hypoxia, nutrient limitation, immune surveillance, and anticancer therapy, reshape methylation programs through metabolic adaptation, and how such remodeling may support phenotypic flexibility and survival under selective pressure. Building upon these advances, we propose the concept of the adaptive methylation landscape, a perturbation-responsive, state-associated, and potentially reversible distribution of methylation states that contributes to shaping the spectrum of cellular states accessible during tumor evolution. Finally, we discuss emerging therapeutic strategies targeting the metabolic-methylation axis and highlight how single-cell multi-omics, spatial epigenomics, functional epigenome editing, and AI may enable dynamic mapping of adaptive methylation landscapes. We propose that cancer cell plasticity is not merely a genetic phenomenon but can also be shaped by metabolically responsive methylation programs, providing a testable conceptual framework for future precision epigenetic therapies.
SN - 2296-634X
ER -